Recombinant Mouse CTLA-4 Fc Chimera Protein Summary
Product Specifications
| Mouse CTLA-4 (Ala37-Phe162) Accession #Q6GTR6 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
6-His tag |
| N-terminus | C-terminus | ||
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
434-CT
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 200 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
434-CT/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
Recombinant Mouse CTLA-4 Fc Chimera inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED50 for this effect is 0.03-0.15 µg/mL when stimulated with 1 µg/mL Recombinant Human B7-1/CD80 Fc Chimera (Catalog # 140-B1).
Reconstitution Calculator
Background: CTLA-4
CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41 ‑ 43 kDa (2) Within the ECD, mouse CTLA-4 shares 94% and 68 ‑ 71% aa sequence identity with rat and human/porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3 ‑ 5). Isoforms of 56 ‑ 79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1-2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7-1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11 ‑ 13).
- Harper, K. et al. (1991) J. Immunol. 147:1037.
- Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
- Magistrelli, G. et al. (1999) Eur. J. Immunol. 29:3596.
- Tector, M. et al. (2009) BMC Immunol. 10:51.
- Oaks, M.K. and K.M. Hallett (2000) J. Immunol. 164:5015.
- Vijayakrishnan, L. et al. (2004) Immunity 20:563.
- Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
- Jansson, A. et al. (2005) J. Immunol 175:1575.
- Darlington, P.J. et al. (2005) J. Immunol. 175:996.
- Platt, A.M. et al. (2010) J. Immunol. 185:1558.
- Wing, K. et al. (2008) Science 322:271.
- Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
- Jain, N. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1524.
Citations for Recombinant Mouse CTLA-4 Fc Chimera Protein
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
12
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Aire suppresses CTLA-4 expression from the thymic stroma to control autoimmunity
Authors: J Morimoto, M Matsumoto, R Miyazawa, H Yoshida, K Tsuneyama, M Matsumoto
Cell Reports, 2022-02-15;38(7):110384.
Species: Mouse
Sample Types: Whole Cells
Applications: Flow Cytometry -
ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models
Authors: A Hanson, K Elpek, E Duong, L Shallberg, M Fan, C Johnson, M Wallace, GR Mabry, S Sazinsky, L Pepper, CJ Shu, S Sathyanara, S Zuerndorfe, T Simpson, M Gostissa, M Briskin, D Law, J Michaelson, CJ Harvey
PLoS ONE, 2020-09-24;15(9):e0239595.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-gamma production in response to mature dendritic cells.
Authors: Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A
J Immunol, 2014-03-31;192(9):4184-91.
Species: Mouse
Sample Types: Whole Cells
Applications: Neutralization -
Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3.
Authors: Kowalczyk A, D'Souza C, Zhang L
Eur J Immunol, 2014-01-22;44(4):1143-55.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Authors: Sandin L, Eriksson F, Ellmark P, Loskog A, Totterman T, Mangsbo S
Oncoimmunology, 2014-01-16;3(1):e27614.
Species: Mouse
Sample Types: Serum
Applications: ELISA (Standard) -
CD86 is an activation receptor for NK cell cytotoxicity against tumor cells.
Authors: Peng, Yanmeng, Luo, Gaoxing, Zhou, Junyi, Wang, Xiaojuan, Hu, Jie, Cui, Yanyan, Li, Xian C, Tan, Jianglin, Yang, Sisi, Zhan, Rixing, Yang, Junjie, He, Weifeng, Wu, Jun
PLoS ONE, 2013-12-11;8(12):e83913.
Species: Mouse
Sample Types: In Vivo
Applications: In Vivo -
TIM-3 does not act as a receptor for galectin-9.
Authors: Leitner, Judith, Rieger, Armin, Pickl, Winfried, Zlabinger, Gerhard, Grabmeier-Pfistershammer, Katharin, Steinberger, Peter
PLoS Pathog, 2013-03-21;9(3):e1003253.
Species: Mouse
Sample Types: Cell Culture Supernates, Whole Cells
Applications: Bioassay -
Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition.
Authors: Khan A, Fu H, Tan L, Harper J, Beutelspacher S, Larkin D, Lombardi G, McClure M, George A
Eur J Immunol, 2013-01-18;43(3):734-46.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Authors: Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ
Immunity, 2007-07-12;27(1):111-22.
Applications: Bioassay -
Induction of CTLA-4-mediated anergy contributes to persistent colonization in the murine model of gastric Helicobacter pylori infection.
Authors: Anderson KM, Czinn SJ, Redline RW, Blanchard TG
J. Immunol., 2006-05-01;176(9):5306-13.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA.
Authors: La Cava A, Ebling FM, Hahn BH
J. Immunol., 2004-09-01;173(5):3542-8.
Species: Mouse
Sample Types: Whole Cells
Applications: Bioassay -
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig.
Authors: Bonham CA, ž²¢6ï[, Peng L, Liang X, Chen Z, Wang L, Ma L, Hackstein H, Robbins PD, Thomson AW, Fung JJ, Qian S, Lu L
2002-09-15;169(6):3382-91.
Species: Mouse
Sample Types: Serum
Applications: ELISA (Standard)
FAQs
-
Can Recombinant Mouse CTLA-4 Fc Chimera Protein (Catalog # 434-CT) be used with human cell lines or any other species?
The activity of Recombinant Mouse CTLA-4 Fc Chimera Protein (Catalog # 434-CT) is measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED50 for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7‑1/CD80 Fc Chimera (Catalog # 140-B1) in the presence of PHA. The product shows activity on the human Jurkat cell line. For human assay systems, please also consider Recombinant Human CTLA-4 Fc Chimera His-tag Protein (Catalog # 325-CT) or Recombinant Human CTLA-4 Fc Chimera (Catalog #7268-CT). Please refer the Citations tab to find publications reporting the use of the protein on other species. Filter the results based on species and sample type for a more relevant search to your target species.
Reviews for Recombinant Mouse CTLA-4 Fc Chimera Protein
Average Rating: 5 (Based on 1 Review)
Have you used Recombinant Mouse CTLA-4 Fc Chimera Protein?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
